178 – Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Background VH3810109 (N6LS) is a broadly neutralizing CD4-binding site antibody in development for ultra-long-acting HIV-1 treatment. The EMBRACE study evaluated efficacy, safety, and tolerability of N6LS every 4 months (Q4M) + monthly intramuscular long-acting cabotegravir (CAB LA) to maintain HIV-1 suppression. Month 6 results showed that intravenous (IV) and subcutaneous (SC) N6LS regimens maintained virologic…